Skip to content
10-K

Annual Report

INOVIO PHARMACEUTICALS, INC. INO

0001055726-26-000008

← back to feed
Filed
Mar 12, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Mar 12, 2026 69.09M sh
Shares Diluted FY 2025 · Dec 31, 2025 46.89M sh
Shares Diluted FY 2025 · Dec 31, 2024 27.16M sh
Capex FY 2025 · Dec 31, 2025 $285.7K
Capex FY 2025 · Dec 31, 2024 $487.83K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$88.63M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$104.08M
Short Term Investments FY 2025 · Dec 31, 2025 $14.24M
Short Term Investments FY 2025 · Dec 31, 2024 $28.3M
Cash And Equivalents FY 2025 · Dec 31, 2025 $44.27M
Cash And Equivalents FY 2025 · Dec 31, 2024 $65.81M
Stockholders Equity FY 2025 · Dec 31, 2025 $24.1M
Stockholders Equity FY 2025 · Dec 31, 2024 $68.5M
Stockholders Equity FY 2025 · Dec 31, 2023 $117.35M
Current Liabilities FY 2025 · Dec 31, 2025 $43.67M
Current Liabilities FY 2025 · Dec 31, 2024 $35.33M
Total Liabilities FY 2025 · Dec 31, 2025 $50.21M
Total Liabilities FY 2025 · Dec 31, 2024 $44.69M
Current Assets FY 2025 · Dec 31, 2025 $61.12M
Current Assets FY 2025 · Dec 31, 2024 $97.83M
Total Assets FY 2025 · Dec 31, 2025 $74.31M
Total Assets FY 2025 · Dec 31, 2024 $113.2M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.81
Eps Diluted FY 2025 · Dec 31, 2024 −$3.95
Eps Basic FY 2025 · Dec 31, 2025 −$1.81
Eps Basic FY 2025 · Dec 31, 2024 −$3.95
Sga Expense FY 2025 · Dec 31, 2025 $32.68M
Sga Expense FY 2025 · Dec 31, 2024 $37M
Rd Expense FY 2025 · Dec 31, 2025 $54.21M
Rd Expense FY 2025 · Dec 31, 2024 $75.62M
Net Income FY 2025 · Dec 31, 2025 −$84.95M
Net Income FY 2025 · Dec 31, 2024 −$107.25M
Operating Income FY 2025 · Dec 31, 2025 −$86.82M
Operating Income FY 2025 · Dec 31, 2024 −$112.4M
Revenue FY 2025 · Dec 31, 2025 $65.34K
Revenue FY 2025 · Dec 31, 2024 $217.76K